Ventajas de la medición de niveles plasmáticos de infliximab en pacientes con enfermedad inflamatoria intestinal / Advantages of level measurement of infliximab in patients with with inflammatory bowel disease
Rev. Hosp. Clin. Univ. Chile
; 27(3): 240-244, 2016.
Article
en Es
| LILACS
| ID: biblio-908191
Biblioteca responsable:
CL36.1
ABSTRACT
Inflammatory bowel disease includes Crohn´s disease, ulcerative colitis and unclassified colitis. Conventional therapies used for treating these diseases are often insufficient orcontraindicated and biological agents have proved to be effective and safe in these cases. Infliximab is a quimeric IgG1 monoclonal anti-tumor necrosis factor antibody that is capableof inducing and mantaining clinical remission in patients with inflammatory bowel disease. Despite its proven efficacy a considerable group of patients lose response requiring changesin therapy. Serum Infliximab trough levels are correlated with clinical response, endoscopic remission and mucosal healing in patients with inflammatory bowel disease. Monitoring and adjusting therapy guided by drug serum levels have proved to be more cost-effective and safer than empiric adjustments. Current international guidelines recommend the measurement of Infliximab trough levels in the global evaluation and management of these patients to improve treatment, avoid adverse events and unnecessary costs.
Texto completo:
1
Índice:
LILACS
Asunto principal:
Enfermedades Inflamatorias del Intestino
/
Infliximab
Tipo de estudio:
Guideline
Límite:
Female
/
Humans
/
Male
Idioma:
Es
Revista:
Rev. Hosp. Clin. Univ. Chile
Asunto de la revista:
MEDICINA
Año:
2016
Tipo del documento:
Article